HOME >> BIOLOGY >> NEWS
2nd annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research awarded to Webster K. Cavenee

(January 17, 2007, Bethesda, MD) -- The National Foundation for Cancer Research (NFCR) announced today that Webster K. Cavenee, Ph.D. has been awarded the 2nd Annual Albert Szent-Gyrgyi Prize for Progress i n Cancer Research. Dr. Cavenee, Director of the Ludwig Institute for Cancer Research and Distinguished Professor at the University of California, San Diego, won the prize for his groundbreaking discoveries regarding the genetic mechanisms of predisposition to human cancer. Dr. Cavenee's research provided the first genetic evidence for the existence of tumor suppressor genes, one of the most influential breakthroughs in cancer research.

The annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research was established to recognize outstanding scientific achievement in the war against cancer and to honor pioneering scientists who have made extraordinary contributions in the field of cancer research. The Prize is designed to draw attention to the continued need to support basic cancer research and the role that it plays in new cancer therapies. The Prize includes a $25,000 honorarium.

"Dr. Cavenee is a pioneer in the truest sense of the word. His research on tumor suppressor genes has not only advanced our understanding of cancer, but it also has provided valuable insight in the role that hereditary predisposition plays into developing cancer," said Dr. Harold Dvorak of Beth Israel Deaconess Hospital and Chair of the Szent-Gyrgyi Prize Selection Committee.

"Dr. Cavenee's discoveries have helped to pave the way for researchers to better break down cancer's complicated molecular structures and understand the role that tumor suppressor genes play in cancer growth and development," said Dr. Sujuan Ba, Co-Chair of the Szent-Gyrgyi Prize Selection Committee and Chief Scientific Officer of NFCR.

Dr. Cavenee's original research seeking to define the genetic lesions in retinoblastoma led to the first hard experimental evi
'"/>

Contact: Silas Deane
sdeane@nfcr.org
National Foundation for Cancer Research
17-Jan-2007


Page: 1 2 3

Related biology news :

1. SNM capitalizes opportunity to meet with policymakers, regulators at annual meeting in D.C.
2. AACR, FDA and NCI announce cancer biomarkers collaborative at the AACR 2007 annual meeting
3. Second annual stem cell symposium to focus on heart tissue, blood diseases
4. Sixth annual bioethics forum to tackle medical applications of research
5. University of Minnesotas 6th annual Design of Medical Devices Conference to be held April 17-19
6. AACR hosts annual meeting 2007
7. Third annual Templeton-Cambridge Fellowships awarded to 10 noted journalists
8. National Academies sessions at AAAS 2007 annual meeting, Feb. 16-19
9. Wiley Foundation announces recipients of 6th annual Wiley Prize in Biomedical Sciences
10. 48th annual Drosophila Research Conference, Philadelphia Marriott, March 7-11, 2007
11. New studies on Alzheimers, autism, nicotine addiction and depression highlight annual meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... ... 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host ... by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... solutions for biopharmaceutical R&D, today announced that it has entered into a ... multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy to ...
(Date:6/23/2020)... KEYNES, England (PRWEB) , ... June 23, 2020 ... ... in Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer ... response project to support testing operations in the fight against the COVID-19 pandemic ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... , ... July 09, 2020 ... ... company, announced today that Massachusetts Institute of Technology (MIT) has expanded the ... license allows PathSensors to move into the point-of-care diagnostic market, focusing initially ...
(Date:7/1/2020)... CHARLOTTE, N.C. (PRWEB) , ... June 29, 2020 ... ... has reported year to date growth of 40% in 2020, despite many obstacles ... medical technology, MedShift aims to increase revenue for its partnered medical practices and ...
(Date:6/28/2020)... (PRWEB) , ... June 25, 2020 , ... ... to advance photodynamic therapy for treating cancer, today announced the company has entered ... (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., ... presented June 22-24 during the American Association for Cancer Research Virtual meeting. One ... the potent, consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
Breaking Biology Technology:
Cached News: